Dexcom, a medical device manufacturer that develops continuous glucose monitoring systems, received a warning letter from the FDA regarding manufacturing processes at its facilities in San Diego and ...

Dexcom, the local maker of continuous glucose monitors, received a warning letter from the Food and Drug Administration last ...

Shares of DexCom Inc. slipped 9.15% to $70.72 Monday, on what proved to be an all-around poor trading session for the stock ...

Medical device maker Dexcom said it has received a warning letter from the U.S. Food and Drug Administration following ...

Dexcom has received a warning letter from the FDA, after the agency uncovered issues during two inspections of the continuous ...

DexCom DXCM received a warning letter from the FDA on March 4, 2025, following inspections of its San Diego and Mesa facilities in 2024. The FDA cited deficiencies in the company’s manufacturing ...

The company does not expect the warning letter to materially impact its manufacturing capacity, sales or ability to seek ...

DexCom received a warning letter from the Food and Drug Administration following inspections of its San Diego and Mesa, Ariz.

Investors with a lot of money to spend have taken a bullish stance on DexCom (NASDAQ:DXCM). And retail traders should know. We noticed this today when the positions showed up on publicly available ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Dexcom stock plunged to a four-month low Monday after the FDA issued a warning letter tied to inspections of two facilities in the U.S. DexCom (NasdaqGS:DXCM) recently received a warning letter ...

DexCom Inc. closed 51.77% below its 52-week high of $142.00, which the company achieved on March 26th.